加密货币交易平台AscendEX创始人曹晶控股的SPAC宣布与Docter合并

　　当地时间10月16日，AscendEX数字资产交易平台创始人曹晶控股的SPAC Aimfinity Investment Corp. I(以下简称：Aimfinity Investment )宣布于10月13日与Docter Inc.(以下简称：Docter )签订了合并协议，预计2024年完成合并。

　　根据协议，交易完成后，假设Aimfinity现有的公共股东没有赎回，则Aimfinity股东将拥有合并后公司约51.92%的股权，Docter股东将在合并后的公司中拥有约48.08%的股权。

　　Docter及其子公司Horn Enterprise Co.， Ltd.一直在开发一种无创血糖趋势监测技术，减轻了血液采样的必要性。该公司运营Docter品牌手表，并采用Docter云平台技术来促进健康监测，血管弹性跟踪和心肌梗塞预测。此外，Docter还投资开发生物雷达波技术，以满足那些需要长期护理或健康状况不佳的个人的需求。

　　Aimfinity Investment 是一家特殊目的收购公司，成立于2021年，2022年在纳斯达克上市，其首席执行官兼董事是AscendEX数字资产交易平台创始人曹晶。

　　曹晶简介

　　Jing (“George”) Cao, our Chief Executive Officer and director, is an experienced technology and finance industry professional. In May 2018, Mr. Cao founded and has since served as the Chief Executive Office of AscendEX, a global digital asset trading platform that offers a variety of products to global users. Since March 2018, he also served as the Chief Executive Officer of HD Consulting Service LLC, a technology consulting service firm in New York, BMXDM Technology PTE. Limited, a technology holdings company for a trading platform, and Global Digital Mercantile Holdings Limited. Prior to these positions, from January 2013 to January 2018, Mr. Cao founded and served as the Chief Investment Officer of Delpha Capital Management, LLC (“Delpha Capital”), a New York based firm that specialized in quantitative trading. Prior to Delpha Capital, from August 2010 to November 2012, Mr. Cao was a senior Portfolio Manager in the Equity Division of Barclays Capital (“Barclays”) in both their New York and London offices. From August 2008 to July 2010, Mr. Cao was a Portfolio Manager at Knight Capital Group where he researched and traded U.S. equities.

　　Mr. Cao earned a Ph.D. in Computer Science from the University of Chicago and a bachelor’s degree in Computer Science and Engineering from the University of Science and Technology of China.